Efficacy and safety of perampanel in generalized and focal to bilateral tonic‐clonic seizures: A comparative study of Asian and non‐Asian populations

Abstract

Summary Perampanel is an approved adjunctive treatment for focal seizures with or without focal to bilateral tonic‐clonic (FBTC) seizures and generalized tonic‐clonic (GTC) seizures. We compared efficacy and safety of perampanel vs placebo in Asian and non‐Asian populations in a post hoc analysis of pooled data from 5 randomized phase 3 studies. Patients (≥12 years old) with focal + FBTC seizures received perampanel 2, 4, 8, or 12 mg or placebo; patients with GTC seizures received perampanel 8 mg or placebo (titration: 4‐6 weeks; maintenance: 13 weeks). Efficacy endpoints included median percentage change in FBTC or GTC seizure frequency per 28 days and 50% responder rate relative to baseline. Median percentage change in FBTC seizure frequency was significantly greater for perampanel 8 and 12 mg than placebo in the Asian population (median difference from placebo: −30.32%, P = 0.0017; −30.06%, P = 0.0008, respectively) and perampanel 4, 8, and 12 mg in the non‐Asian population (−35.07%, P = 0.0001; −37.78%, P < 0.0001; −34.53%, P < 0.0001, respectively). In both populations, median percentage change in GTC seizure frequency was significantly greater for perampanel 8 mg than placebo (median difference from placebo: Asian, −37.37%, P = 0.0139; non‐Asian, −27.04%, P = 0.0006). The 50% responder rates were significantly greater than placebo for perampanel 8 and 12 mg for FBTC seizures (Asian: 58.0%, P = 0.0017 and 58.6%, P = 0.0013, respectively; non‐Asian: 59.3%, P < 0.0001 and 54.3%, P = 0.0050, respectively) and perampanel 8 mg for GTC seizures (Asian: 57.6%, P = 0.0209; non‐Asian: 68.8%, P = 0.0329). Pooled FBTC/GTC seizure data showed generally similar patterns of response to perampanel in both populations. The most frequent treatment‐related adverse events were fatigue, irritability, dizziness, somnolence, and headache. Perampanel was effective, well tolerated, and can be considered a therapeutic option for FBTC/GTC seizures in Asian populations.

Effectiveness of perampanel as the only add‐on: Retrospective, multicenter, observational real‐life study on epilepsy patients

“…This study comprised 503 PWE, of whom a consistent portion of almost 200 subjects received PER as early (first or second) add-on ASM. The data from the present study have to be compared with several retrospective studies on PER use in real-life practice, [7][8][9][10][11][12][13][14][15] with different characteristics.…”

The EpiPick algorithm to select appropriate antiseizure medications in patients with epilepsy: Validation studies and updates

“…The updated algorithm takes into account that (a) cenobamate was approved by the U.S. Food and Drug Administration (FDA) for the treatment of focal seizures in adults 5 ; (b) new evidence indicates that lacosamide is efficacious and safe as a treatment option for primary generalized tonic-clonic (GTC) seizures in patients with idiopathic generalized epilepsy (IGE) 6 ; and (c) new data show that perampanel is efficacious and safe as a treatment option for primary GTC seizures in patients with IGE. 7 The revisions include the following:…”

Red blood cell distribution width predicts in-hospital mortality in patients with a primary diagnosis of seizures in the ICU: a retrospective database study

“…The lifetime prevalence of active epilepsy is reported to be 7.60 per 1000 persons [2]. In 2016, epilepsy affected 45 million people worldwide, and the agestandardized mortality rate of idiopathic epilepsy was 126 per 100,000 people [3]. Some patients with epilepsy, including status epilepticus, must be admitted to the intensive care unit (ICU).…”